Please login to the form below

Not currently logged in
Email:
Password:

Sandoz

This page shows the latest Sandoz news and features for those working in and with pharma, biotech and healthcare.

Amgen wins Enbrel patent case, knocking back Sandoz's biosimilar plan

Amgen wins Enbrel patent case, knocking back Sandoz's biosimilar plan

Sandoz thinks Amgen obtained the patients in “an attempt to extend its US compound patent protection for etanercept to 2029”. ... Sandoz respectfully disagrees with the Court’s ruling,” said Carol Lynch, president of Sandoz US.

Latest news

More from news
Approximately 20 fully matching, plus 170 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    radioligands and CAR‐T for cancer. $2.1B. Sale. Aurobindo. NovartIs sold part of Sandoz’s US generics. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the ophthalmology products.

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    In Ciba-Geigy/Sandoz, the FTC was concerned that the merger could impair the development of gene therapy, a market that the FTC forecast to be worth US$45bn within 20 years

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’ Sandoz a tilt at the

  • Deal Watch November 2016 Deal Watch November 2016

    In May this year Sandoz announced that a regulatory submission for its version of rituximab had been accepted by the EMA following multiple clinical trials in over 800 patients.

  • Deal Watch October 2016 Deal Watch October 2016

    Even without non-exclusive deals from one supplier, there is the additional competitive risk of new biosimilar entrants, such as Sandoz, etcetera.

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 18 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics